Biostar to market UTI test:
This article was originally published in Clinica
Biostar will market Meridian Diagnostics' one-minute urinary tract infection test, FiltraCheck-UTI, to the US outpatient market. Privately-owned Biostar, based in Boulder, Colorado, will have exclusive rights to the test for the alternate site market, where over 60 million urinary screening tests are performed each year in the US. Meridian, which will manufacture the tests for Biostar, will continue to market it to hospitals and commercial laboratories. An application has been filed with the FDA for approval to sell FiltraCheck-UTI over-the-counter, for which Johnson & Johnson's Direct Access Diagnostics has marketing rights.
You may also be interested in...
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.